Cargando…

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice

SIMPLE SUMMARY: FGFR inhibitors evolved as therapeutic options in cholangiocarcinoma and urothelial malignancies. Given the implications of FGFR pathway in various physiological functions, FGFR inhibitors are known to cause unique toxicities. In this review, we summarized the physiology of FGF/FGFR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kommalapati, Anuhya, Tella, Sri Harsha, Borad, Mitesh, Javle, Milind, Mahipal, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231807/ https://www.ncbi.nlm.nih.gov/pubmed/34199304 http://dx.doi.org/10.3390/cancers13122968

Ejemplares similares

Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
por: Tella, Sri Harsha, et al.
Publicado: (2019)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
por: Tella, Sri Harsha, et al.
Publicado: (2022)

Contemporary Management of Localized Resectable Pancreatic Cancer
por: Kommalapati, Anuhya, et al.
Publicado: (2018)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
por: Mahipal, Amit, et al.
Publicado: (2019)

Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations
por: Storandt, Michael H, et al.
Publicado: (2022)

Thyrotoxic Periodic Paralysis: An Underdiagnosed and Under-recognized Condition
por: Tella, Sri Harsha, et al.
Publicado: (2015)

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis
por: Tella, Sri Harsha, et al.
Publicado: (2017)

Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer
por: Tella, Sri Harsha, et al.
Publicado: (2017)

Aspirin and Statin Use and the Risk of Gallbladder Cancer
por: Prasai, Kritika, et al.
Publicado: (2021)

Anti–PD-L1 Treatment Induced Central Diabetes Insipidus
por: Zhao, Chen, et al.
Publicado: (2017)

Upper Limb Phlegmasia Cerulea Dolens Secondary to Heparin-induced Thrombocytopenia Leading to Gangrene
por: Kommalapati, Anuhya, et al.
Publicado: (2018)

Updates in Gastrointestinal Oncology – insights from the 2008 44(th )annual meeting of the American Society of Clinical Oncology
por: Javle, Milind, et al.
Publicado: (2009)

Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology
por: Javle, Milind, et al.
Publicado: (2010)

A glimpse into the future of esophageal carcinoma in the United States: predicting the future incidence until 2040 based on the current epidemiological data
por: Tella, Sri Harsha, et al.
Publicado: (2023)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer
por: Mehta, Rutika, et al.
Publicado: (2020)

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma
por: Tella, Sri Harsha, et al.
Publicado: (2023)

Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017
por: Javle, Milind, et al.
Publicado: (2022)

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
por: Qu, Lingzhi, et al.
Publicado: (2022)

Type 2M Von Willebrand Disease: A Case Report
por: Ghosh, Sudeshna, et al.
Publicado: (2018)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

THU535 Anti-angiogenic Multi-kinase Inhibitor In NUTM1 Rearranged Carcinoma Of Thyroid
por: Tella, Sri Harsha, et al.
Publicado: (2023)

LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy
por: Zuo, Mingxin, et al.
Publicado: (2015)

Clinical development and management of adverse events associated with FGFR inhibitors
por: Subbiah, Vivek, et al.
Publicado: (2023)

SAT-596 Hypothyroidism with Recurrent Pericardial Effusion Due to Medication Noncompliance
por: Singhi, Ryan, et al.
Publicado: (2019)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
por: Abboud, Karen, et al.
Publicado: (2023)

Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer
por: Abdel-Wahab, Reham, et al.
Publicado: (2020)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Cardio-oncology: management of cardiovascular toxicity
por: Markman, Timothy M., et al.
Publicado: (2019)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer
por: Packer, Leisl M., et al.
Publicado: (2019)

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines
por: Mohamed, Amr, et al.
Publicado: (2022)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma
por: Chun, Yun Shin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s3ejmih2agn3te98msr2r2l701